Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ASPC
ASPC logo

ASPC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
11.870
Open
11.670
VWAP
11.39
Vol
11.41K
Mkt Cap
25.48M
Low
11.150
Amount
129.99K
EV/EBITDA(TTM)
--
Total Shares
2.34M
EV
24.61M
EV/OCF(TTM)
--
P/S(TTM)
--
A SPAC III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to pursue prospective targets that are in the environmental, sustainability and governance (ESG) and material technology sector.
Show More

Events Timeline

(ET)
2026-01-27
10:20:00
SPAC III Acquisition Corp Trading Halted Due to Volatility
select
2026-01-02 (ET)
2026-01-02
12:40:00
SPAC III Acquisition Corp Trading Halted Due to Volatility
select
2025-12-30 (ET)
2025-12-30
10:00:00
SPAC III Acquisition Corp Trading Halted Due to Volatility
select
2025-12-29 (ET)
2025-12-29
09:40:00
SPAC III Acquisition Corp Trading Halted Due to Volatility
select
2025-12-26 (ET)
2025-12-26
09:40:00
SPAC III Acquisition Corp Trading Halted Due to Volatility
select

News

Benzinga
2.0
01-27Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
  • Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
  • Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
  • Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
  • Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Benzinga
5.0
2025-12-31Benzinga
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
  • FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
  • Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
  • Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
  • Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Benzinga
9.5
2025-12-29Benzinga
Mereo BioPharma Shares Plunge 87.5% After Phase 3 Study Fails to Meet Primary Endpoints
  • Study Failure: Mereo BioPharma's Phase 3 ORBIT and COSMIC studies failed to achieve statistical significance in reducing clinical fracture rates, causing shares to plummet 87.5% to $0.29 in pre-market trading, severely undermining market confidence in the company.
  • Partner Impact: Ultragenyx Pharmaceutical, a partner of Mereo, also saw its shares drop 43.7% to $19.26, reflecting investor pessimism about the drug's prospects, which may affect future collaborations and funding for research and development.
  • Market Reaction: Other related stocks, such as SPAC III Acquisition Corp and Sellas Life Sciences, experienced declines of 11.7% and 7.6%, respectively, indicating a broader erosion of confidence in the biotech sector among investors.
  • Investor Sentiment: The failure of Mereo's studies has dampened investor sentiment in the biotech field, potentially leading to capital outflows and stricter financing conditions that could hinder the growth of other companies in the industry.
Benzinga
7.0
2025-12-29Benzinga
Bolt Projects Raises FY2026 Sales Guidance to $11 Million
  • Sales Guidance Increase: Bolt Projects raised its FY2026 sales guidance from $9 million to $11 million, reflecting the company's confidence in future growth, which is likely to attract more investor interest.
  • Fourth Quarter Sales Forecast: The company anticipates fourth-quarter sales of $2.7 million, and this positive outlook may further drive stock price increases, enhancing market confidence.
  • Strong Stock Price Reaction: Bolt Projects' shares surged 28.2% to $1.73 in pre-market trading, indicating a bullish market sentiment towards the company's prospects, potentially drawing in more institutional investors.
  • Market Dynamics Impact: The strong performance of Bolt Projects contrasts sharply with the volatility of other stocks, highlighting its relative strength in the current market environment, which may enhance its competitive position within the industry.
Benzinga
2.0
2025-12-26Benzinga
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
  • Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
  • Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
  • Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
  • Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
Benzinga
9.5
2025-12-26Benzinga
Biohaven Reports Phase 2 Study Failure for BHV-7000, Stock Drops
  • Study Results Disappoint: Biohaven Ltd. (NYSE:BHVN) reported on Friday that its Phase 2 trial for BHV-7000 targeting major depressive disorder failed to meet its primary endpoint, resulting in a 10.4% drop in stock price, reflecting market concerns over the drug's development prospects.
  • Market Volatility: On the same day, industrial stocks fell by 0.2%, indicating uncertainty in the economic outlook, which could impact investor confidence and future capital flows.
  • Diverse Stock Performance: While Biohaven's stock declined, shares of Davis Commodities Ltd. (NASDAQ:DTCK) surged by 105.6% following the release of its financial results, highlighting a divergence in market reactions to different companies.
  • Overall Market Dynamics: The Dow Jones index fell by 0.1%, while the NASDAQ and S&P 500 indices rose by 0.12% and 0.11%, respectively, suggesting a complex market sentiment as investors navigate between sectors.

Valuation Metrics

The current forward P/E ratio for A SPAC III Acquisition Corp (ASPC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess A SPAC III Acquisition Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.06
Current PS
0.00
Overvalued PS
0.85
Undervalued PS
-0.73

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock currently have a small float.
Intellectia · 2908 candidates
Floating Shares: <= 50,000,000
Ticker
Name
Market Cap$
top bottom
STRC logo
STRC
Strategy Inc
42.03B
CAPS logo
CAPS
Capstone Holding Corp
5.24M
DIT logo
DIT
Amcon Distributing Co
71.58M
BH.A logo
BH.A
Biglari Holdings Inc
1.23B
SLGL logo
SLGL
Sol Gel Technologies Ltd
172.80M
SEB logo
SEB
Seaboard Corp
4.77B

Whales Holding ASPC

W
W. R. Berkley Corporation
Holding
ASPC
+7.32%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is A SPAC III Acquisition Corp (ASPC) stock price today?

The current price of ASPC is 11.15 USD — it has increased 2.29

What is A SPAC III Acquisition Corp (ASPC)'s business?

A SPAC III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to pursue prospective targets that are in the environmental, sustainability and governance (ESG) and material technology sector.

What is the price predicton of ASPC Stock?

Wall Street analysts forecast ASPC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASPC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is A SPAC III Acquisition Corp (ASPC)'s revenue for the last quarter?

A SPAC III Acquisition Corp revenue for the last quarter amounts to -152.43K USD, decreased -71.79

What is A SPAC III Acquisition Corp (ASPC)'s earnings per share (EPS) for the last quarter?

A SPAC III Acquisition Corp. EPS for the last quarter amounts to -191282.00 USD, decreased -46.11

How many employees does A SPAC III Acquisition Corp (ASPC). have?

A SPAC III Acquisition Corp (ASPC) has 0 emplpoyees as of March 10 2026.

What is A SPAC III Acquisition Corp (ASPC) market cap?

Today ASPC has the market capitalization of 25.48M USD.